FOE OR FRIEND? SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS AND COVID-19 VACCINATION: A SYSTEMATIC REVIEW

Received 2023-06-12; Accepted 2023-12-26; Published 2024-08-01

Authors

  • Maureen Miracle Stella Medical Profession Study Programme, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
  • Caroline Tanadi Medical Profession Study Programme, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
  • Kevin Tandarto School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
  • Kenny Wijaya Sutanto Medical Profession Study Programme, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
  • Cindy Oey Department of Internal Medicine, St. Carolus Hospital, Jakarta, Indonesia.

DOI:

https://doi.org/10.22452/jummec.vol27no2.7

Keywords:

SLE, COVID-19 vaccination, Antibody response, Disease status

Abstract

Background: In the early year of 2020, SARS-CoV-2 was first diagnosed in Indonesia after an outbreak in Wuhan, China. Later, this disease became a worldwide pandemic. Systemic lupus erythematosus (SLE) patients are more vulnerable to COVID-19. They are also prone to relapse and have lower efficacy for COVID-19 immunization.

Objective: This study aimed to evaluate the antibody seroconversion and disease status after COVID-19 vaccination in SLE patients.

Method: We followed the PRISMA guidelines to systematically search and collect literature in the following databases: ProQuest, PubMed, EBSCOhost, SAGE, JSTOR, and ScienceDirect from 1st January 2019 to 24th April 2023. Titles and abstracts were reviewed for relevance. The inclusion criteria are original articles, written in English, investigated the effects of COVID-19 vaccination in SLE patients. The quality of evidence was evaluated using the Newcastle-Ottawa Scale.

Results and Discussion: From 1,088 studies, we retrieved nine studies for this review. There were cohort studies (n = 5), case-control studies (n = 2), and observational studies (n = 2) published between 2021 and 2022. Vaccines against SARS-CoV-2 are currently widely available and SLE patients should receive vaccination. In a large study involving healthy individuals and healthcare professionals, nearly all of the individuals who received two doses of BNT162b2 developed antibodies to the vaccine. Seroconversion after a first COVID-19 vaccination is delayed in older patients on specific immunosuppressive drugs.

Conclusion: This systematic review found that the overall immunogenicity and safety of COVID-19 vaccines were satisfactory in patients with SLE.

Downloads

Download data is not yet available.

Author Biographies

Maureen Miracle Stella, Medical Profession Study Programme, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.

 

 

Kevin Tandarto, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.

 

 

Kenny Wijaya Sutanto, Medical Profession Study Programme, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.

 

 

Cindy Oey, Department of Internal Medicine, St. Carolus Hospital, Jakarta, Indonesia.

 

 

Downloads

Published

2024-08-01

Issue

Vol. 27 No. 2 (2024)

Section

Research article

License

All authors agree that the article, if editorially accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0 to allow others to freely access, copy and use research provided the author is correctly attributed, unless otherwise stated. All articles are available online without charge or other barriers to access. However, anyone wishing to reproduce large quantities of an article (250+) should inform the publisher. Any opinion expressed in the articles are those of the authors and do not reflect that of the University of Malaya, 50603 Kuala Lumpur, Malaysia.